# Phase 1 Norwalk Vaccine Study

> **NCT00806962** · PHASE1 · COMPLETED · sponsor: **LigoCyte Pharmaceuticals, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Norovirus

## Interventions

- **DRUG:** Adjuvant/Excipients
- **DEVICE:** placebo
- **BIOLOGICAL:** Norwalk VLP Vaccine
- **BIOLOGICAL:** Norwalk VLP Vaccine

## Key facts

- **NCT ID:** NCT00806962
- **Lead sponsor:** LigoCyte Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2015-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00806962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00806962, "Phase 1 Norwalk Vaccine Study". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00806962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*